You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東曜藥業-B(01875.HK):維梧資本擬認購公司附屬曜展新增註冊資本50萬美元
格隆匯 01-07 22:24

格隆匯1月7日丨東曜藥業-B(01875.HK)宣佈,於2022年1月7日,公司、Vivo Capital Fund VIII與曜展訂立增資協議,據此,Vivo Capital Fund VIII同意以現金注資方式認購曜展新增註冊資本50萬美元。

曜展目前為公司的全資附屬公司,並將於增資完成後成為公司的非全資附屬公司。曜展為公司的全資附屬公司,主要從事腫瘤藥物諮詢服務、市場推廣及銷售。其擁有合營公司華曜的47%權益。

據悉,維梧資本(Vivo Capital LLC)作為Vivo Capital Fund VIII的管理公司,全力支持且樂意推動集團銷售及營銷戰略轉型,從而為集團業務發展提供資金保障。通過增資,維梧資本將能夠深入支持曜展業務發展,從而促進集團創新抗腫瘤藥物銷售及營銷業務的發展。Vivo Capital Fund VIII的現金注資金額乃經參考曜展及華曜未來一段時間的資金需求而釐定,預期將用於支持及發展曜展及華曜的業務。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account